scanX
Home
Alembic Pharmaceuticals

Alembic Pharmaceuticals

897.00
-34.25
(-3.68%)
search
Market Cap
17,631.71 Cr
EPS
31.33
PE Ratio
30.76
Dividend Yield
1.18 %
Industry
Healthcare
52 Week High
1,303.90
52 Week Low
725.20
PB Ratio
3.74
Debt to Equity
0.13
Add Ratio
Live Chart
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy+33.33 %
+33.33 %
Hold+55.56 %
+55.56 %
Sell+11.11 %
+11.11 %

Company News

View All News
Caret
positive
Alembic Pharma's API-III Facility Passes USFDA Inspection4 days ago
Alembic Pharmaceuticals has successfully completed a scheduled Good Manufacturing Practice (GMP) inspection by the US Food and Drug Administration (USFDA) for its API-III facility located in Karakhadi. The inspection concluded without any Form 483 observations, indicating no significant objectionable conditions or practices were found.
positive
Alembic Pharmaceuticals: API Facility Passes USFDA Inspection6 days ago
Alembic Pharmaceuticals' API-III facility in Karakhadi, Gujarat successfully completed a scheduled USFDA GMP inspection without any Form 483 observations. The inspection took place from March 17 to 21.

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Sun Pharmaceutical
1,725.40
#1 4,13,981.26
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.16
Divis Laboratories
5,771.95
1,53,227.14
75.20
8,184.00
0.89
1,600
#1 64.53
56.90
Cipla
1,448.40
1,16,974.95
24.00
26,520.70
14.17
4,155
47.38
51.80
Torrent Pharmaceuticals
3,213.65
1,08,764.52
58.64
10,785.70
11.59
1,656
13.54
59.74
Mankind Pharma
2,421.80
99,918.27
49.78
10,615.60
19.57
1,942
-16.38
59.91
Dr Reddys Laboratories
1,147.50
95,753.75
#1 18.06
28,905.40
12.36
5,578
1.69
47.74
Lupin
2,005.35
91,552.44
32.14
20,141.50
#1 19.94
1,936
38.82
47.45
Zydus Life Science
884.60
89,011.46
19.77
19,831.50
13.82
3,831
29.92
42.86
Aurobindo Pharma
1,153.85
67,015.80
19.21
29,559.20
17.55
3,169
-10.04
53.81
Abbott
30,759.65
65,362.11
48.70
6,097.20
10.80
1,201
16.01
55.29
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
80.06 %
Cash Flow Change
10.95 %
ROE
63.22 %
ROCE
54.94 %
EBITDA Margin (Avg.)
22.28 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
504
582
1,003
918
630
737
880
777
742
648
797
840
854
863
1,129
1,022
930
952
1,241
1,210
1,243
1,342
1,460
1,317
1,306
1,328
1,313
1,291
1,426
1,263
1,475
1,510
1,407
1,498
1,605
1,634
1,521
1,564
1,678
1,703
Expenses
405
478
629
532
484
580
702
632
606
547
610
653
680
712
825
776
749
757
895
884
926
934
1,014
949
960
1,090
1,054
1,030
1,268
1,255
1,244
1,274
1,203
1,288
1,387
1,364
1,257
1,325
1,409
1,433
EBITDA
99
103
375
386
146
158
178
146
136
102
187
188
174
151
305
246
181
195
346
326
318
408
447
368
346
238
259
261
158
9
231
236
205
210
218
269
263
239
270
270
Operating Profit %
19 %
18 %
37 %
42 %
23 %
21 %
20 %
19 %
18 %
16 %
23 %
22 %
20 %
18 %
27 %
24 %
19 %
20 %
28 %
27 %
23 %
30 %
30 %
28 %
25 %
18 %
18 %
19 %
10 %
1 %
16 %
16 %
14 %
13 %
13 %
16 %
17 %
15 %
15 %
15 %
Depreciation
11
13
13
22
24
19
21
21
22
22
26
26
32
28
29
29
30
35
36
42
44
42
44
47
51
53
55
56
123
67
68
67
74
66
68
69
70
69
71
70
Interest
0
1
1
1
2
1
1
1
2
1
0
1
1
2
6
6
5
5
7
7
8
7
5
2
3
2
5
4
7
9
12
15
14
14
16
15
11
13
19
22
Profit Before Tax
89
91
362
364
120
137
157
124
112
79
161
161
141
122
270
211
146
155
303
276
266
360
398
318
292
183
200
201
29
-67
151
155
116
130
135
185
183
157
180
178
Tax
18
19
73
95
29
33
37
37
19
12
39
30
47
32
70
42
23
36
52
49
62
66
73
33
49
24
36
29
7
-2
18
33
-36
9
-2
4
5
23
27
40
Net Profit
70
72
289
269
91
104
120
87
93
67
122
131
94
90
200
169
124
120
250
227
204
293
325
286
243
158
164
172
22
-66
133
122
153
121
137
180
178
135
153
138
EPS in ₹
3.73
3.72
15.30
14.26
4.82
5.50
6.36
4.59
4.94
3.54
6.45
6.93
4.98
4.80
10.61
9.01
6.58
6.56
13.06
12.42
11.93
15.99
17.24
14.88
12.75
8.37
8.34
8.74
1.11
-3.35
6.78
6.20
7.76
6.14
6.95
9.23
8.48
6.84
7.79
7.01
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
Fixed Assets
547
708
799
993
1,159
1,552
1,788
1,798
2,398
2,547
Current Assets
891
1,511
1,373
1,825
1,958
2,463
2,652
2,861
2,910
3,079
Capital Work in Progress
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
Investments
0
53
50
42
49
18
236
118
96
93
Other Assets
1,011
1,575
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,282
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
Current Liabilities
684
747
693
1,144
1,490
1,752
1,281
1,717
1,637
1,455
Non Current Liabilities
72
84
94
576
570
1,047
361
168
175
172
Total Equity
885
1,597
1,902
2,220
2,718
3,190
5,067
5,238
4,371
4,818
Reserve & Surplus
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
Share Capital
38
38
38
38
38
38
39
39
39
39
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
Investing Activities
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
Operating Activities
172
948
329
312
812
449
1,463
552
724
803
Financing Activities
87
-224
-129
503
59
155
-597
-217
-262
-438
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
69.48 %
69.48 %
69.48 %
69.48 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.52 %
4.46 %
4.32 %
3.94 %
4.17 %
DIIs
10.92 %
11.17 %
11.36 %
11.56 %
11.69 %
12.06 %
12.43 %
12.76 %
13.31 %
13.40 %
13.93 %
14.50 %
15.38 %
15.47 %
16.05 %
16.06 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.99 %
10.78 %
11.43 %
9.57 %
9.22 %
8.91 %
9.12 %
9.21 %
9.08 %
8.98 %
8.24 %
8.00 %
7.41 %
7.48 %
7.36 %
7.26 %
Others
8.61 %
8.57 %
7.73 %
9.39 %
9.47 %
9.41 %
8.84 %
8.42 %
8.00 %
8.01 %
8.22 %
3.37 %
3.14 %
3.13 %
3.04 %
2.90 %
No of Share Holders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 4 4 5.5 10 14 10 8 11 0.00
Dividend Yield (%) 0.00 0.73 0.74 1.03 1.04 1.89 2.13 0.81 1.18 0.00

Corporate Action

Announcements

Closure of Trading Window1 day ago
Successful Completion Of USFDA Inspection At Alembic Pharmaceuticals Limited API-III Facility At Karakhadi6 days ago
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 201510 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report10 days ago
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot10 days ago
Completion Of USFDA Inspection At Alembic Pharmaceuticals LimitedS Bioequivalence Facility At VadodaraMar 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Solid Oral Formulation Facility (F-4) At JarodFeb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 11, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Announcement under Regulation 30 (LODR)-RetirementFeb 04, 2025
Integrated Filing (Financial)Feb 03, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 03, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Results For The Quarter And Nine Months Ended 31St December 2024Feb 03, 2025
Board Meeting Outcome for Outcome Of The Board MeetingFeb 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024.Jan 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 06, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 01, 2025
Intimation For Change Of Name Of Registrar And Share Transfer Agent (RTA) Of The CompanyJan 01, 2025
Announcement Under Regulation 30 Of SEBI LODR, Regulations 2015Dec 17, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 12, 2024
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015Dec 11, 2024
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Dec 06, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 04, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 02, 2024
US FDA Inspection At Alembic Pharmaceuticals Limited' Solid Oral Formulation Facility (F-4) At JarodNov 23, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 15, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 12, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 07, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 07, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 07, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2024
Unaudited Financial Results For The Quarter And Half Year Ended September, 2024Nov 07, 2024
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 04, 2024

Technical Indicators

RSI(14)
Neutral
61.33
ATR(14)
Volatile
40.91
STOCH(9,6)
Neutral
73.16
STOCH RSI(14)
Neutral
69.39
MACD(12,26)
Bullish
17.44
ADX(14)
Strong Trend
28.18
UO(9)
Bearish
62.61
ROC(12)
Uptrend And Accelerating
12.82
WillR(14)
Neutral
-26.00
Bearish
2
Neutral
4
Bullish
3

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across chronic segments, including Dermatology, Anti-Infective, Cardiology, and Anti-Diabetic therapies. The company has manufacturing facilities in Gujarat and Sikkim, with research and development centers in Vadodara, Hyderabad, and New Jersey. Alembic has expanded its operations through acquisitions, joint ventures, and international subsidiaries, focusing on developing and marketing generic drugs in various global markets.
Website
http://www.alembicpharmaceuticals.com/
Chairperson NameChirayu R Amin
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Price & Volume Screeners
Intraday Screeners
Candlestick Screeners
Technical Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.